ublituximab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
monoclonal antibodies (chimeric origin); tumor	5697	1174014-05-1

Description:

Molecule	Description
Molfile Synonyms: ublituximab ublituximab-xiiy briumvi TG-1101 LFB-R603 TGTX-1101	The precise mechanism by which ublituximab-xiiy exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ublituximab-xiiy results in cell lysis through mechanisms including antibody-dependent cellular cytolysis and complement-dependent cytolysis. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Molfile

Synonyms:

ublituximab
ublituximab-xiiy
briumvi
TG-1101
LFB-R603
TGTX-1101

The precise mechanism by which ublituximab-xiiy exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ublituximab-xiiy results in cell lysis through mechanisms including antibody-dependent cellular cytolysis and complement-dependent cytolysis.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 31, 2023	EMA	PROPHARMA GROUP THE NETHERLANDS B.V.
Dec. 28, 2022	FDA	TG THERAPEUTICS, INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AA57	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Relapsing forms of multiple sclerosis	indication	426373005	DOID:2378
Viral hepatitis type B	contraindication	66071002	DOID:2043

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
B-lymphocyte antigen CD20	Surface antigen	P11836	CD20_HUMAN	BINDING AGENT				UNKNOWN	DRUG LABEL

External reference:

ID	Source
CHEMBL2108354	ChEMBL_ID
C000619007	MESH_SUPPLEMENTAL_RECORD_UI
C549677	MESH_SUPPLEMENTAL_RECORD_UI
8920	IUPHAR_LIGAND_ID
DB11850	DRUGBANK_ID
019257	NDDF
4041960	VANDF
4041961	VANDF
C4083151	UMLSCUI
CHEMBL2109348	ChEMBL_ID
9334	INN_ID
D11243	KEGG_DRUG
2626348	RXNORM
364480	MMSL
41161	MMSL
d09959	MMSL
U59UGK3IPC	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
BRIUMVI	HUMAN PRESCRIPTION DRUG LABEL	1	73150-150	INJECTION, SOLUTION, CONCENTRATE	150 mg	INTRAVENOUS	BLA	27 sections